← Back to Calendar

Protagonist Therapeutics Q4 2025 Earnings

Protagonist Therapeutics · $PTGX
Standard Review Earnings
Catalyst Date
February 25, 2026
Date Status
47d ago (past)
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 3m ago · Data: FMP
Current Price
$98.82 +141.67%
+$57.93 today
Day: $98.40 – $104.28
Market Cap
N/A
Shares out: 63.81M
Float: 51.94M
52-Week Range
$41.28
$107.84
Current price is at 86% of 52-week range
Avg Volume
784K
Beta
2.11
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $PTGX catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + rusfertide REVIVE Phase 3 update

Key Notes

Q4 2025 earnings reported February 25, 2026. Key milestones: REVIVE Phase 3 trial in polycythemia vera ongoing — data expected H2 2026. Rusfertide hepcidin mimetic program on track.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar